Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients

Current Evidence of Anti–Tumor Necrosis Factor α Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta‐Analysis Approach of Individual Drugs

“…These reasons included that patients were not naive to anti-TNF␣, that outcome measures were not extractable (32)(33)(34), and/or that the articles did not refer specifically to children, even if the study population included children (e.g., studies of Behçet's disease [35,36] or other secondary ocular inflammation [37]). Díaz-Llopis et al reported one of the largest prospective studies on ADA efficacy in refractory chronic uveitis, including 39 JIA children among 131 enrolled patients (38). In line with our results, this study assessed a significant reduction of uveitis activity, gain in visual acuity, and overall decrease of steroid and/or immunosuppression load on ADA treatment.…”

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

“…25 A multicenter prospective study of 131 patients with a mean age of 27 years also demonstrated that adalimumab therapy significantly improved anterior chamber and vitreous inflammation with the ability to taper CS. 14 The French uveitis network recently published a multicenter observational study of 160 patients with refractory uveitis treated with anti-TNFα (infliximab and adalimumab) agents. The patients had an overall response rate of 93% at 12 months.…”

“…13 Several prospective studies, including the VISUAL I clinical trial, have shown the efficacy and safety of anti-TNF agents (infliximab and adalimumab) in the treatment of chronic and refractory uveitis and in reducing CS use. [14][15][16][17][18][19] There are two major therapeutic goals in uveitis: (1) To achieve quiescence in an eye with active intraocular inflammation, which was the focus of the VISUAL I trial. (2) To prevent a recurrence of intraocular inflammation, and reduce side effects of long-term CS usage in patients with a history of uveitic flare controlled by oral CS (≥10mg/d) treatment.…”

Cytokine Profiles in Aqueous Humor and Plasma of HIV-infected Individuals with Ocular Syphilis or Cytomegalovirus Retinitis

“…Intravitreal drugs targeting different cytokines for the treatment of local inflammation in chronic non-infectious uveitis have given promising results. [34][35][36][37][38] Identification of the cytokines involved in the pathogenesis of different OIs in HIV-infected individuals has important implications for the development of drugs targeting these cytokines, particularly in cases of persistent inflammation after successful treatment of active ocular infections.…”